Cadrenal TherapeuticsCVKD
13F holders, Q2 2026 (June 30)3holders
1new positions
1sold out
$3.34avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, unchanged from Q1 2026. 1 opened new positions and 1 sold out. The largest holders were CoreCap Advisors, LLC ($4K), Farther Finance Advisors, LLC ($84) and Caldwell Sutter Capital, Inc. ($17).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 1 | $512 |
All 13F filers, Q1 2026 → Q2 2026: 1,285 shares bought and 100 shares sold, net +1,185 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| CoreCap Advisors, LLC | 0.00% | New | 1,285 | $4K |
| Farther Finance Advisors, LLC | 0.00% | No change | 25 | $84 |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 5 | $17 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.